Compare DexCom, Inc. (DXCM) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Advanced Drainage Systems Inc — how do they compare? DexCom, Inc. trades at $84.97 (market cap $31.86B), while Advanced Drainage Systems Inc trades at $125.66 (market cap $9.52B). The key difference: DexCom, Inc. is far larger — about 3.3× Advanced Drainage Systems Inc's market cap, and Advanced Drainage Systems Inc pays a 0.63% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Advanced Drainage Systems Inc for 43 Days on average.
| DXCM | WMS | |
|---|---|---|
Market Cap | $31.86B | $9.52B |
Volume | 3,607,070 | 907,564 |
Sector | Health | Basic Materials |
52-Week High | $92.34 | $175.38 |
52-Week Low | $54.84 | $125.33 |
Typical Hold Time | 62 Days | 43 Days |
Enterprise Value | $31.32B | $11.12B |
Dividend Yield | — | 0.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Advanced Drainage Systems (WMS) trades at $126.36, up 0.22% with a bearish technical signal despite strong fundamental performance. The company reported Q2 2026 EPS of $2.49, beating estimates by 18.6%, continuing a trend of earnings outperformance. Key financial metrics show robust profitability with 14% net income margin and 24.9% ROE, though cash flow turned negative in 2025 due to increased capital investments. Recent news highlights sustainability initiatives and institutional positioning changes.
WMS presents a compelling investment case with consistent earnings beats and strong analyst support ($188.70 price target), but faces near-term technical headwinds and cash flow pressures from aggressive expansion. The stock's current valuation at 21.5x P/E appears reasonable given growth prospects, though investors should monitor execution of NDS integration and capital allocation strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
